Next-Generation Nanobody Therapeutic Targeting EGFR and IGF1R for Breast Cancer

VHH-P855 is a cutting-edge humanized nanobody therapeutic currently advancing through biological testing, with strong therapeutic potential in breast cancer. This innovative program precisely targets both the epidermal growth factor receptor (EGFR) and the insulin like growth factor 1 receptor (IGF1R), two clinically significant proteins implicated in cancer growth and resistance mechanisms. By combining the selectivity and binding strength of nanobodies with the strategic dual targeting of EGFR and IGF1R, VHH-P855 aims to address key challenges in breast cancer treatment and offers a promising new strategy for tackling refractory disease.

Licensing Opportunity

VHH-P855 is actively available for out-licensing or strategic collaboration opportunities. We invite partners in the biotech and pharmaceutical sectors to contact us for further discussion of joint development or commercialization.

Development Phase

Modality

VHH-P855 leverages a state-of-the-art modality by encapsulating an IGF1R inhibitor within liposomes that are further conjugated with nanobodies directed against EGFR. The nanobody, characterized by its small molecular size and single-domain structure, provides high tissue penetration and remarkable stability compared to conventional antibodies. This modular configuration enables enhanced targeting specificity and cell entry, facilitating more effective delivery of therapeutic payloads to tumor cells expressing EGFR and IGF1R. Such properties are particularly advantageous in breast cancer, where intratumoral heterogeneity and the tumor microenvironment can impede the efficacy of larger molecules.

Target

EGFR and IGF1R are membrane-associated tyrosine kinase receptors that play central roles in cellular proliferation, survival, and differentiation. EGFR is predominantly found in epithelial tissues and is frequently overexpressed in various solid tumors, including breast cancer, where it correlates with aggressive disease features. IGF1R is widely expressed in both normal and malignant cells and modulates cellular growth pathways implicated in oncogenesis and therapy resistance. The pathological upregulation of EGFR and IGF1R contributes to tumor progression and therapeutic evasion in breast cancer. VHH-P855's dual-targeting of EGFR and IGF1R holds significant strategic value, as it addresses key nodes in oncogenic signaling networks, thereby potentially overcoming primary mechanisms of resistance and improving therapeutic outcomes.

Mechanism of Action

VHH-P855 operates via a multimodal mechanism: its nanobody component selectively binds EGFR on tumor cell surfaces, enabling precise delivery of liposome-encapsulated IGF1R inhibitor to malignant cells. The synchronized inhibition of EGFR and IGF1R disrupts critical signal transduction pathways that drive cancer cell proliferation, survival, and metastasis. Interrupting these pathways may lead to reduced tumor growth and increased cancer cell sensitivity to further therapeutic interventions. As a nanobody-based platform, VHH-P855 can be further developed into antibody-drug conjugates or bispecific therapeutics, extending its application across diverse solid tumors where EGFR and IGF1R play pathogenic roles.

Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women worldwide and remains a leading cause of cancer-related morbidity and mortality. It encompasses a heterogeneous group of malignancies, with variable biological behaviors and responses to therapy. The current treatment landscape includes surgery, radiation, chemotherapy, endocrine therapy, and targeted biological agents. Despite significant advancements, challenges such as therapeutic resistance, disease recurrence, and limited efficacy in specific subgroups persist. Targeted agents against EGFR and IGF1R have demonstrated varying success, but optimal control of aggressive or refractory disease remains elusive. VHH-P855 promises to address these unmet needs by leveraging dual-target inhibition via a nanobody-liposome system, with the potential to overcome resistance mechanisms and provide sustained disease control in breast cancer patients.